Advertisement

Clinical and Translational Oncology

, Volume 10, Issue 8, pp 462–467 | Cite as

Endocrine therapy of metastatic breast cancer

  • Laura Rodríguez LajusticiaEmail author
  • Miguel Martín Jiménez
  • Sara López-Tarruella Cobo
Educational Series

Abstract

Breast cancer growth and dissemination is regulated by estrogen and different growth factor receptor signalling pathways. The increasing knowledge of the biology of breast cancer regarding the interaction of these signalling pathways provides a tool to understand endocrine therapies response and resistance mechanisms. In patients with slowly progressive disease, no visceral involvement, and minimal symptoms, endocrine therapy could be the strategy of choice, even if the tumor has low estrogen receptor expression. Ovarian suppression and tamoxifen are recommended for premenopausal patients whether aromatase inhibitors are the option for postmenopausal ones. Chemotherapy still remains as the right alternative for hormone unresponsive or resistant patients. This is a review focused on the different strategies and combinations of endocrine therapies for metastatic breast cancer patients considering the potential strategies clinically tested to overcome resistance and the different treatments of choice available for each scenario of disseminated disease.

Keywords

Metastatic breast cancer Endocrine therapy Hormonal receptors HER 2 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Smith I (2006) Goals of treatment for patients with metastatic breast cancer. Semin Oncol 33:2–5CrossRefGoogle Scholar
  2. 2.
    Kataja VV, Colleoni M, Bergh J (2005) ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer. Ann Oncol 16:10–12CrossRefGoogle Scholar
  3. 3.
    Robertson JG, Willsher PC, Cheung KL et al (1997). The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 33:1774–1779PubMedCrossRefGoogle Scholar
  4. 4.
    Beatson GW (1896) On the treatment of inoperable cases of carcinoma of the mama: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107, 162–165.CrossRefGoogle Scholar
  5. 5.
    Klijn JG, Berns PM, Bontenbal M et al (1992) Clinical breast cancer, new developments in selection and endocrine treatment of patients. J Steroid Biochem Mol Biol 43:211–221PubMedCrossRefGoogle Scholar
  6. 6.
    Prowell TM, Davidson NE (2004) What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist 9:507–517PubMedCrossRefGoogle Scholar
  7. 7.
    Ingle JN, Krook JE, Green SJ et al (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178–185PubMedGoogle Scholar
  8. 8.
    Buchanan RB, Balmey RW, Durrant KR et al (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326–1330PubMedGoogle Scholar
  9. 9.
    Swaka CA, Pritchard KI, Shelly W et al (1997) A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res Treat 44:211–215CrossRefGoogle Scholar
  10. 10.
    Taylor CW, Green S, Dalton WS et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16:994–999PubMedGoogle Scholar
  11. 11.
    Boccardo F, Rubagotti A, Perotta A et al (1994) Ovarian ablation versus goserelin with or without tamoxifen in pre and perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 5:337–342PubMedGoogle Scholar
  12. 12.
    Jonat W, Kauffmann M, Balmey RW et al (1995) A randomized study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre and perimenopausal patients with advanced beast cancer. Eur J Cancer 31:137–142CrossRefGoogle Scholar
  13. 13.
    Klijn JG, Beex LV, Mauriac L et al (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92:903–911PubMedCrossRefGoogle Scholar
  14. 14.
    Klijn JG, Balmey RW, Boccardo F et al (2001) Combined tamoxifen and luteinising hormone releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343–353PubMedGoogle Scholar
  15. 15.
    Sunderland MC, Osborne CK (1991) Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 9:1283–1297PubMedGoogle Scholar
  16. 16.
    Milla-Santos A, Milla L, Rallo L et al (2001) Phase III randomized trial of toremifene vs tamoxifen in hormonodependent advanced breast cancer. Breast Cancer Res Treat 65:119–124PubMedCrossRefGoogle Scholar
  17. 17.
    Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197PubMedCrossRefGoogle Scholar
  18. 18.
    Vogel VG, Constantino JP, Wickerman DL et al (2006) Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727–2741PubMedCrossRefGoogle Scholar
  19. 19.
    Howell A, DeFriend D, Robertson J et al (1995) Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345: 29–30PubMedCrossRefGoogle Scholar
  20. 20.
    Wetanabe T, Sano M, Ohno S et al (2004) Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study. Anticancer Res 24:1275–1280Google Scholar
  21. 21.
    Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605–1613PubMedCrossRefGoogle Scholar
  22. 22.
    Howell A, Robertson JFR, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396–3403PubMedCrossRefGoogle Scholar
  23. 23.
    Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:2286–2295CrossRefGoogle Scholar
  24. 24.
    Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98:229–238PubMedCrossRefGoogle Scholar
  25. 25.
    Inge JN, Suman VJ, Rowland KM et al (2006) Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24:1052–1056CrossRefGoogle Scholar
  26. 26.
    Gradishar WJ, Chia S, Piccart-Gebhart MJ et al (2006) Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. Breast Cancer Res 100:8–9Google Scholar
  27. 27.
    Robertson JFR, Semiglazov V, Nemsadze G et al (2007) Effects of fulvestrant 250mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 43: 64–70PubMedCrossRefGoogle Scholar
  28. 28.
    Young OE, Renshaw L, Macaskill EJ et al (2008) Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 44:391–399PubMedCrossRefGoogle Scholar
  29. 29.
    Pritchard KI (2000) Current and future directions in medical therapy for breast carcinoma. Cancer 12:3065–3072CrossRefGoogle Scholar
  30. 30.
    Mauri D, Pavlidis N, Polyzos NP et al (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer. Meta-analysis. J Natl Cancer Inst 98:1285–1291Google Scholar
  31. 31.
    Kaufmann M, Bajetta E, Dirix LY et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double blind trial. J Clin Oncol 18: 1399–1411PubMedGoogle Scholar
  32. 32.
    Buzdar AU, Jones SE, Vogel CL et al (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79:730–739Google Scholar
  33. 33.
    Jonat W, Howell A, Blomquist C et al (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32:404–412CrossRefGoogle Scholar
  34. 34.
    Bonneterre J, Thurlimann B, Robertson JF et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 18:3748–3757PubMedGoogle Scholar
  35. 35.
    Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758–3767Google Scholar
  36. 36.
    Bonnetere J, Buzdar A, Nabholtz JM et al (2002) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247–2258CrossRefGoogle Scholar
  37. 37.
    Mouridsen HT (2007) Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 105:19–29PubMedCrossRefGoogle Scholar
  38. 38.
    Rose C, Vtoraya O, Pluzanska A et al (2003) An open randomised trial of second line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318–2327PubMedCrossRefGoogle Scholar
  39. 39.
    Paridaens R, Therasse P, Dirix L et al (2004) First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients. A randomized phase III trial of the EORTC Breast Group. ASCO Annual Meeting Proceedings. J Clin Oncol 22:515AGoogle Scholar
  40. 40.
    Bertelli G, Garona O, Merlano M et al (2005) Sequential treatment with exemestane and non-steroideal aromatase inhibitors in advanced breast cancer. Oncology 69:471–477PubMedCrossRefGoogle Scholar
  41. 41.
    Stein RC, Dowsett M, Hedley A et al (1990) The clinical and endocrine effects of 4-hydroxyadndrostendione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 62:679–683PubMedGoogle Scholar
  42. 42.
    Celio L, Martinetti A, Ferrari L (1999) Premenopausal breast cancer patients treated with a gonadotrophin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 19:2261–2268PubMedGoogle Scholar
  43. 43.
    Forward DP, Cheung KL, Jackson L et al (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590–594PubMedCrossRefGoogle Scholar
  44. 44.
    Muss HB, Case LD, Alkins JN et al (1994) Tamoxifen versus high dose medroxiprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol 12:1630–1638PubMedGoogle Scholar
  45. 45.
    Wolf G, Rieche K (1978) Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testosterone-drostanolone. Onkologie 1:172–174Google Scholar
  46. 46.
    Massarweh S, Schiff R (2006) Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 13:15–24CrossRefGoogle Scholar
  47. 47.
    Osborne CK, Schiff R (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23:1616–1622PubMedCrossRefGoogle Scholar
  48. 48.
    Marcom PK, Isaacs C, Harris L et al (2007) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102:43–49PubMedCrossRefGoogle Scholar
  49. 49.
    Kaufman B, Mackey J, Clemens M et al (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC). In: Proceedings from 31st ESMO Congress, Istanbul 2006. LBA2Google Scholar

Copyright information

© Feseo 2008

Authors and Affiliations

  • Laura Rodríguez Lajusticia
    • 1
    Email author
  • Miguel Martín Jiménez
    • 1
  • Sara López-Tarruella Cobo
    • 1
  1. 1.Servicio de Oncología MédicaHospital Clínico Universitario San CarlosMadridSpain

Personalised recommendations